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Abstract
Context: Steroidogenic acute regulatory protein (StAR) is crucial for transport of cholesterol to mitochondria where
biosynthesis of steroids is initiated. Loss of StAR function causes lipoid congenital adrenal hyperplasia (LCAH).
Objective: StAR gene mutations causing partial loss of function manifest atypical and may be mistaken as familial
glucocorticoid deficiency. Only a few mutations have been reported.
Design: To report clinical, biochemical, genetic, protein structure and functional data on two novel StAR mutations, and to
compare them with published literature.
Setting: Collaboration between the University Children’s Hospital Bern, Switzerland, and the CIBERER, Hospital Vall
d’Hebron, Autonomous University, Barcelona, Spain.
Patients: Two subjects of a non-consanguineous Caucasian family were studied. The 46,XX phenotypic normal female was
diagnosed with adrenal insufficiency at the age of 10 months, had normal pubertal development and still has no signs of
hypergonodatropic hypogonadism at 32 years of age. Her 46,XY brother was born with normal male external genitalia and
was diagnosed with adrenal insufficiency at 14 months. Puberty was normal and no signs of hypergonadotropic
hypogonadism are present at 29 years of age.
Results: StAR gene analysis revealed two novel compound heterozygote mutations T44HfsX3 and G221S. T44HfsX3 is a loss-
of-function StAR mutation. G221S retains partial activity (,30%) and is therefore responsible for a milder, non-classic
phenotype. G221S is located in the cholesterol binding pocket and seems to alter binding/release of cholesterol.
Conclusions: StAR mutations located in the cholesterol binding pocket (V187M, R188C, R192C, G221D/S) seem to cause
non-classic lipoid CAH. Accuracy of genotype-phenotype prediction by in vitro testing may vary with the assays employed.
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Introduction
Mutations in the StAR gene were first described in patients with
classic congenital lipoid adrenal hyperplasia (CLAH) in which
both the adrenals and the gonads seemed to completely lack
steroidogenesis [1]. The underlying pathophysiology of CLAH is
explained by the defective transport of cholesterol needed for the
biosynthesis of steroids, to the inner mitochondrial membrane, and
the cytoplasmic accumulation of lipid droplets which would fatally
harm the cells of the steroidogenic tissues over time [2]. So far,
patients described as having the recently described non-classic
form of lipoid adrenal hyperplasia (NCLAH) presented with
adrenal insufficiency in early infancy or later and, while
manifesting with hypocortisolism, had inconsistent signs of
mineralocorticoid deficiency [3,4,5], thus resembling the clinical
profile of familial glucocorticoid deficiency (FGD). FGD has been
described as a syndrome secondary to ACTH resistance, and
inactivating mutations in the gene encoding melanocortin type 2
receptor (MC2R) were the first to be associated with FGD [6].
However, only ,25% of such patients were found to be the
carriers of MC2R mutations and have been classified as type 1
FGD [7]. A second genetic cause of FGD was identified in 15–
20% of patients resulting from defects in the MC2R receptor
accessory protein (MRAP) (FGD type 2) [7,8]. In the remaining
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MC2R or MRAP genes were found. Large family association
studies delimited a region on chromosome 8q12.1–q21.2 that was
associated with the FGD syndrome in several families (FGD type
3) [9]. The StAR gene maps to the gene locus 8p11.2 and has been
identified only recently as causing non-classic lipoid adrenal
hyperplasia in a first series of patients in 5 families [4]. In contrast
to CLAH which leads to a complete undervirilization/feminiza-
tion of the external genitalia in 46,XY subjects at birth, most
46,XY patients with the NCLAH seem to have a normal gonadal
function during their fetal life and therefore have normal male
genitalia at birth or show only minimal anomalies such as
cryptorchidism or hypospadias [3,4,5]. However, some patients
that were followed to adulthood showed a progressive decline in
the gonadal functions over time, as demonstrated by decreasing
plasma testosterone, high gonadotropins and abnormal spermio-
gram [4].
To better understand whether a StAR mutation will lead to the
severe form of CLAH or whether it will manifest as NCLAH
mimicking a FGD syndrome, further patients need to be studied
and followed as they age. On the other hand, patients manifesting
with a FGD syndrome who do not have mutations in the genes for
MC2R and MRAP should be genetically investigated for StAR
mutations.
In this report, we have studied a series of 7 patients (6 families)
who had the clinical and biochemical diagnosis of congenital
isolated glucocorticoid deficiency, for possible genetic defects. The
MC2R gene analysis revealed a novel homozygous MC2R
mutation (K289fs) in one patient [10]. The MRAP gene
sequencing showed a normal sequence in all 7 patients. The StAR
gene analysis revealed two novel mutations (T44HfsX3 and
G221S) present in compound heterozygote form in two siblings.
Here we are describing the clinical, genetic and functional
characteristics of these novel StAR mutations.
Materials and Methods
Case Reports
Patient 1. A Caucasian phenotypically normal female was the
first child of non-consanguineous parents, born in 1978 after an
uneventful pregnancy and a normal neonatal period. At 10
months of age, she experienced an episode of dehydration and
hypoglycemia accompanied by skin hyperpigmentation: blood
glucose 23 mg/dl (1.27 mmol/L), plasma sodium 127 mmol/L,
potassium 4.5 mmol/L, urea 75 mg/dL (12.4 mmol/L). Fifteen
days later she suffered a similar episode. The cortisol levels did not
respond to stimulation with ACTH [250 mg perfused over 4 h,
followed by 250 mg IM/12 h for the following 2 days]: baseline
2.3 mg/dL (63.4 nmol/L) followed by 3.7 mg/dL (102.1 nmol/L)
at 15 h, 1.9 mg/dL (52.4 nmol/L) at 24 h, 2.1 mg/dL (57.9 nmol/
L) at 48 h and 1.4 mg/dL (38.6 nmol/L) at 72 h. The ACTH was
not measured and baseline plasma renin activity was 22 ng/mL/h
(28.5 nmol/L/h; normal range: 1.1–22.9 ng/mL/h). Karyotype
was 46,XX. She was diagnosed with congenital adrenal
hyperplasia and was treated with hydrocortisone (18–20 mg/
m
2/d) and fludrocortisone (50 mg/d); doses were adjusted during
childhood and puberty according to the growth and the renin
activity control. Pubertal development started at 12 years of age,
menarche presented at 14 years, total pubertal growth gain was
14 cm and a final height of 143 cm was reached at the age of 16
years (midparental height 147.2 cm). Currently, at the age of 32
years, she is doing fine on hydrocortisone (10 mg/m
2/d) and
fludrocortisone (50 mg/d) replacement treatment, has regular
menses and normal serum gonadotropin concentrations at early
follicular phase (LH 2.6 IU/L and FSH 4.2 IU/L); the ACTH is
un-measurable.
Patient 2. The younger brother of patient 1, was born in 1981
after an uneventful pregnancy. He had normal male genitalia and
descended testes. At 3 weeks of life, a SynacthenH (250 mg/1.73 m
2
iv) test showed a normal cortisol response: baseline 2.5 mg/dL
(68.9 nmol/L) and peak 19.5 mg/dL (538.0 nmol/L). However, at
14 months of age he presented with hypoglycemic episodes and
skin hyperpigmentation. ACTH was elevated [.1250 pg/mL
(.275 pmol/L)], cortisol did not respond to ACTH stimulation
[basal 3.1 mg/dL (85.5 nmol/L); peak 3.4 mg/dL (93.8 nmol/L)]
and plasma renin activity was normal [4.2 ng/mL/h (5.4 nmol/L/
h)]. He was treated with hydrocortisone (16–18 mg/m
2/d) and
fludrocortisone (50 mg/d) during childhood and puberty. Puberty
started at 11.5 years of age, hydrocortisone dose was adjusted to
10 mg/m
2/d to improve growth, total pubertal growth gain was
31 cm and he reached a final height of 159.3 cm (midparental
height 160.7 cm). At 17 years of age, fludrocortisone therapy was
stopped and plasma renin activity remained normal thereafter.
Presently, at the age of 29 years, he is fine on only hydrocortisone
therapy. Bilateral testicular volume is 25 mL. Serum testosterone is
669 ng/dL (23.1 nmol/L; normal range 262–1600 ng/dL), LH 7.3
IU/L (normal range 0.8–8.0), FSH 7.2 IU/L (normal range 0.7–
12.0), inhibin B 138.2 pg/mL (normal range 107–322 pg/mL),
androstendione 150 ng/dL (5.2 nM/L; normal range 70–250 ng/
dL), DHEA ,70 ng/dL (,2.4 nmol/L; normal range 400–
800 ng/dL); DHEA-S ,15 mg/dL (,384 nmol/L; normal range
60–410 mg/dL); ACTH is 12 pg/mL (2.6 pmol/L) under cortisol
replacement therapy.
MC2R, MRAP and StAR gene analysis
The study was approved by the ethics committee of the Hospital
Vall d’Hebron, Barcelona, Spain, where the human studies were
performed. Written informed consent of patients and families was
obtained for genetic analysis of FGD. Leukocyte genomic DNA
was prepared and the genes for MC2R, MRAP and StAR were
analyzed, exon by exon, using specific primers and PCR
amplification as previously described [1,2,11,12]. The PCR-
amplified products were purified and sequenced with an
automated sequencer (ABI PRISM 3100 Genetic Analyzer,
Applied Biosystems, Madrid, Spain) using a BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the
specifications provided by the manufacturer. The primers used for
sequencing were the same as those used for PCR. The sequences
were compared with the NCBI entries of MC2R (NM_000529),
MRAP (NW_927384) and StAR (NG_011827.1).
In vitro functional studies
Vectors expressing cDNAs of wild-type (wt) StAR and the fusion
protein P450 side-chain cleavage/adrenodoxin/adrenodoxin re-
ductase (F2) were a kind gift of Walter L. Miller, UCSF, San
Francisco [1,13]. Vectors expressing mutant StAR cDNA were
generated by PCR-based, site-directed mutagenesis and confirmed
by direct sequencing. Nonsteroidogenic COS-1 cells (CRL-
1650
TM; http://www.atcc.org) were cultivated in DMEM (Invi-
trogen, Basel, Switzerland) supplemented with 10% fetal calf
serum and antibiotics at 37uC. Cells were divided onto 12-well
plates and grown overnight before transfection. Transfection with
wt or mutant (T44H_S46X, G221S) StAR expression vectors in
combination with F2 was performed with Lipofectamin 2000
(Invitrogen, Basel, Switzerland) in growth medium without
antibiotics overnight. Transfected cells were then cultivated for
another 24 hours. For assessing pregnenolone (Preg) production,
cells were washed with phosphate buffered saline (PBS) and placed
Novel G221S StAR Mutation Mimics FGD
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were then collected over a time range of 5–600 min. Vector
without StAR cDNA served as negative background control and
the StAR-independent substrate 22R-hydroxycholesterol (22R
OH-Chol) (Sigma-Aldrich, Buchs, Switzerland) added to the cell
culture medium provided a positive control. Pregnenolone was
determined by a commercially available ELISA (Labor Diagnos-
tika Nord GmbH & Co, KG, Nordhorn, Germany). Sensitivity of
this assay is 5 ng/dl. Data represent the mean 6 SEM of 2
independent experiments performed in duplicates. Accuracy of
this ELISA for pregnenolone measurement from culture medium
was tested against pregnenolone measurements performed by
GC/MS [14].
Western blot
Fourty-eight hours after transfection, supernatants were col-
lected and cells were washed with PBS and lysed. Protein content
of the cell lysates was determined by the Bradford method (Biorad,
Reinach, Switzerland). Protein lysates were separated on a 10%
SDS-PAGE gel and transferred on a polyvinylidene difluoride
membrane. Membrane was then incubated with a primary StAR
antibody at a 1:109000 dilution (kindly provided by Walter L.
Miller, San Francisco) and then with a goat-anti-rabbit secondary
antibody at 1:59000 conjugated to HRP (Santa Cruz, Santa Cruz,
CA, USA). The HRP signal was detected by an enhanced
chemiluminescence staining (ECL, Amersham) and exposure to
Amersham Hyperfilm MP (Amersham, GE Healthcare, Buck-
inghamshire, UK).
Structural modeling of StAR
3D protein models of N-62 StAR. The 3D structural model
of StAR (NP_000340.2, P49675) sequence (62–285 AA) was
based on the structures of StAR related lipid transfer domain of
MLN64 [15] and human StAR related lipid transfer protein 5
(1EM2-A and 2R55-A) that share high sequence similarity with
human StAR proteins as obtained by 5 rounds of PHI BLAST
iterated search of protein structure database. We performed
several structural alignment with both template protein sequences
that were then used for model building with the programs
YASARA [16] and WHATIF [17]. First a secondary structure
prediction of the StAR amino acid sequence was performed for
correcting the alignment and for building the loops in the modeled
structures with the program DSC [18]. A total of 10 different
alignments (5 with each protein) were made and used for building
ten different models. After building side chains, each model was
subjected to first a steepest and then simulated annealing
minimization for carrying out small refinement of the models.
During this stage all backbone atoms of the aligned residues were
Figure 1. Genetic analysis of the StAR gene. Upper panel, scheme of the identified mutations at the nucleotide (c.DNA) and protein (p.) level.
Lower panel, family tree with individual electropherograms showing the novel StAR mutations.
doi:10.1371/journal.pone.0020178.g001
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corrected models were then subjected to a 100 ps simulated
annealing energy minimization and then checked by the programs
WHATCHECK [19], WHATIF [17], Verify3D [20,21], ERRAT
[22] and Ramachandran plot analysis [23,24]. Coordinates of two
template crystal structures (PDB# 1EM2 and 2R55) were used for
comparative studies. After looking at the quality control results a
hybrid model incorporating best quality models was made and
refined by a 500 ps MD simulation. The MD simulations were
performed using YASARA dynamics using AMBER03 force field
[16]. In brief the cell was filled with water and the AMBER03 [25]
electrostatic potentials was evaluated at all water molecules and
ones with the lowest or highest potential were turned into a sodium
or chloride counter ion until the cell was neutral. We then ran MD
simulations with AMBER03 force field at 298 K and 0.9% NaCl
in the simulation cell for 500 ps to refine the final model.
Simulation trajectories were analyzed with WHATIF functions
and snapshots of simulation were captured every 25 ps for further
analysis. Best models were selected for analysis and evaluation of
mutant amino acids. Computational site directed mutagenesis was
performed using side chain optimizations by simulated annealing
simulations energy minimizations and MD simulations over
500 ps. Structure models were depicted with Pymol (www.
pymol.org) and rendered as ray traced images with POVRAY
(www.povray.org).
Steered MD simulation to study release of bound
cholesterol by StAR
Final StAR-cholesterol complex obtained after docking and MD
refinement was used to study the release of cholesterol by steered MD
simulations. The cholesterol molecule was extracted from the StAR
cavitybyapplyingaconstantforceonthecholesterolmoleculetodrive
it away from StAR during MD simulations. In brief, a force was
applied on the center of cholesterol molecule to pull it away.
Simulation was conducted with pH 4.0 to mimic the binding
environmentofStARusedinbiochemicalexperiments and adistance
range of 7.5–35A ˚. Experiment was repeated with S221-StAR.
Results
Identification of two novel StAR [c.125_126insG
(p.Thr44HisfsX3) and c.661G.A (p.Gly221Ser)] mutations
Two siblings initially suspected as having FGD, in whom MC2R
and MRAP sequences were normal, were compound heterozygote
carriers of two novel mutations in the StAR gene. A novel
frameshift mutation in exon 2, c.125_126insG predicting
p.Thr44HisfsX3 or T44H_S46X and a novel point mutation in
exon 6, c.661G.A predicting p.Gly221Ser were identified
(Figure 1). Analysis of the parents demonstrated that the exon 2
mutation was carried by the father while the exon 6 mutation was
present on one allele in the mother (Figure 1).
Figure 2. Secondary structural and amino acid conservation of human StAR. (A) A secondary structure prediction was performed to start
the model building of human StAR. Locations of amino acids variants of StAR found in UniProt database and pubmed are indicated. (B) A partial
sequencing alignment of human StAR amino acid sequence with a range of StAR proteins from other species found in the UniProt database. Overall,
StAR amino acid sequence is very well conserved across species with only occasional difference showing up across whole alignment. All major
residues at cholesterol binding pocket, E169, R188, R192 and T223 are conserved in all species studied in this analysis, while H220 was found to be
replaced with an asparagine in Chicken and Zebrafish, potentially conserving the core structural elements.
doi:10.1371/journal.pone.0020178.g002
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We performed a PhiBlast search of PDB database with the
amino acid sequence of human StAR. A custom position specific
scoring matrix (PSSM) was created based on initial runs of the Phi-
BLAST and after five rounds of search optimizations, the human
StAR related lipid transfer domain of MLN64 (PDB # 1EM2)
and StAR related lipid transfer 5 (PDB # 2R55) structures were
chosen as template based on structure quality and coverage of
human StAR sequence. A secondary structure prediction of the
human StAR sequence was performed to start the initial alignment
(Figure 2). Amino acids 62 to 285 of the human StAR molecule
were aligned with template structures to generate structural
alignments of two molecules and fed into the YASARA and
WHATIF programs for building of models. Some of the loop
sequences were modelled separately by scanning loop database
library. In the final model of StAR a total of 6 loops were modelled
(LLGSRLEETL, QQDNGD, RMEAMG, VPDV, GSP, HPA-
SEARC). Quality control analysis revealed 98.7% of residues in
favoured regions and 100% residues in the allowed regions of the
Ramachandran plot. Our StAR model was close to MLN64 in
terms of core structural features and was also in agreement with
previously described models of StAR (Figure 3) [26,27,28]. These
previous models of StAR have also been based on MLN64
structure which was used as a template in our model building, and
therefore, based on reported features, our model was quite similar
in overall fold and geometry as compared to previous reports, and
had similar steroid binding pocket, preserving core salt bridges
between E169 and R188 [26,27]. Changes in refinement protocols
like use of newer amber2003 forcefield in our work compared to
older amber99 forcefield used by Yaworsky et al [28,29] may have
resulted in minor changes in the modelling of side chains and inter
atomic constraints. However, due to exponential increase in
computational power available, we were able to use newer
generation refinement algorithms, resulting in a final model that is
of similar quality to a high resolution crystal structure. Another
main difference in our model building have been the use of
information in PDB_REDO database (http://swift.cmbi.ru.nl/gv/
pdbredo/index.html) which re-refines the structures in PDB
database using latest methods using the original structural data
deposited in PDB, which tends to be several years old, and corrects
the errors in structures found in PDB database [30,31]. For the
MLN64 structure (PDB # 1EM2), the overall Ramachanran plot
appearance changed from 20.543 to 0.433 for the optimized entry,
and total number of bumps/structural clashes were reduced from
61 in the original entry to 22, Chi-1/Chi-2 rotamer normality
improved from 22.029 to 0.106, and R-free value changed from
0.2640 to 0.2115 in the optimized version used by us.
Structural changes caused by the G221S mutation
To study the effect of the novel and some known StAR
mutations, we performed computational mutagenesis of our
structural model of StAR. To explore the role of mutations in
binding and release of cholesterol by StAR, a docking of
cholesterol into the StAR structure was performed and used to
calculate the interactions with neighbouring amino acids forming
the cholesterol binding pocket. Several hydrogen bonds with the
hydroxyl group of cholesterol and side chains of amino acids
forming the cavity holding the cholesterol seem to form during
entry and exit of cholesterol. In our simulation, E169, R188,
H220, T223 and S244 located on the beta sheets of the cholesterol
binding cavity next to helix 3 were found to be involved in the
interactions with cholesterol (Figure 4A). In addition, other
potential interaction partners of cholesterol were N150 L260
and T263. In previous studies mutations of E169, R188 and L260
(E168 and R187 in case of hamster StAR) have been reported to
result in loss of cholesterol transfer activity of StAR [2,3,5,26].
Among these core residues, R188 forms salt bridges with E169 and
H220, and two hydrogen bonds with E169, one of which was not
found in G221S-StAR, although all salt bridges were intact. A
slight but significant shift in the core binding site upon G221S
mutation was observed due to disruption of G221–S244 hydrogen
bond which seems to cause change in conformation of H220 side
chain and disrupt interaction of H220 with cholesterol in the
S221-StAR compared to WT-StAR as revealed by all atom
contact analysis (Figure 4B). This change is likely to have resulted
from additional contacts of S221 with V116 which are absent in
WT StAR.
Entry and exit of cholesterol in StAR
Potential routes of cholesterol entry and exit were also evaluated
to fully understand the role of StAR mutation (G221S) described
in this study. After docking of cholesterol into StAR, we performed
a steered molecular dynamic simulation, where a constant force on
cholesterol molecule was applied during simulation. We observed
considerable movement of the loop formed by residues A174–
L178 of StAR, but not of the C-terminus helix during the exit of
cholesterol bound to StAR. An earlier report using the forced
disulfide bond formation has indicated flexibility of C-terminus
helix based on cholesterol binding studies with WT and
structurally constrained StAR proteins [29]. Another recent
computational molecular dynamic simulation study on binding
and exit of cholesterol from StAR found movement of the A174–
L178 loop but not the C-terminus helix [27], suggesting a possible
rigid nature of the C-terminus helix. However, structures of both
WT and structurally constrained StAR proteins reported by Baker
Figure 3. Model of StAR protein showing reported, non-classic
StAR mutations. Mutations manifesting clinically with NCLAH and
having .10% WT StAR activity in a direct functional assay (V187M,
R188C, R192C, G221S) are depicted in red. Mutations A218V, M225T,
F267S, L275P, for which clinical and functional results are conflicting,
are given in blue. StAR loss-of-function mutation L260P is given in black
for comparison.
doi:10.1371/journal.pone.0020178.g003
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cholesterol binding was due to putting constraints on C-terminus
helix or by the subtle structural changes caused by the restraints
created by artificially introduced disulfide bonds as suggested by
Murcia et al [27]. Additional studies involving mutagenesis of
amino acids in the loop formed by AA174–178 of StAR will also
be required to investigate the potential mechanisms of cholesterol
binding. We also observed interaction of cholesterol with R188
and T223 in WT and R188, T223 and S221 in G221S-StAR
(Figure 5). Steered molecular dynamic simulations showed a slight
but consistent delay of 2 ps in the release of cholesterol from the
S221-StAR compared to WT StAR (10 versus 8 ps). Further
analysis of cholesterol binding by looking at all the contacts
revealed additional contacts between C5 and C6 of cholesterol
molecule and R188 in case of S221-StAR that may be responsible
for this delay. Therefore, potential mechanism for the partial loss
Figure 4. A closeup of the cholesterol binding pocket of StAR. After docking of cholesterol to both WT (A) and S221-StAR (B), we calculated
potential residues interacting with cholesterol molecule during docking as well as exit of cholesterol from the binding cavity. In case of S221-StAR a
loss of interaction with H220 was observed due to a shift in the H220 side chain. Cholesterol is shown as a ball and stick model in magenta. Amino
acids interacting with cholesterol are shown as stick models.
doi:10.1371/journal.pone.0020178.g004
Figure 5. Exit of cholesterol from StAR as studied by steered
MD simulations. StAR protein is shown as a ribbons model colored in
a rainbow gradient from the amino terminus in blue to carboxy
terminus in red. The A174–V179 loop that was observed to move and
make way for the exit of cholesterol is shown in grey. Major amino acids
involved in interaction of cholesterol with StAR and formation of
cholesterol binding pocket are shown as stick models. The exit route of
cholesterol observed during simulation is shown as a solid model in red.
In case of S221-StAR a delay in exit of cholesterol was observed,
potentially due to altered binding pattern caused by shift in H220 side
chain and additional interactions with R188.
doi:10.1371/journal.pone.0020178.g005
Figure 6. Functional testing of the identified StAR mutations in
vitro. COS-1 cells were transiently transfected with expression vectors
for the side chain cleavage system (F2) and wild-type (WT) or mutant
StAR. A) Protein expression was assessed by Western blot. B) The ability
to produce pregnenolone (Preg) was measured in the cell supernatants
after 5–600 min using a commercially available ELISA assay. Results are
given as mean 6 SD. StAR independent Preg production of the cell
system was assessed by using empty vector/F2 and adding 22(R)-
hydroxycholesterol (22R OH-Chol) to the cell medium.
doi:10.1371/journal.pone.0020178.g006
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binding/release of the cholesterol molecule resulting from
structural changes in the cholesterol binding pocket. It is possible
that multiple modes of cholesterol binding and exit may exist in
the function of StAR protein as suggested by two different models
[27,29] and any impairments caused by mutations may affect one
or both of the mechanisms of cholesterol binding and exit in the
StAR protein.
Functional analysis of the novel StAR mutants in vitro
To assess the impact of the newly identified StAR mutations on
steroidogenesis, we generated expression vectors and compared
their ability to promote pregnenolone production to wt StAR in an
established cellular model [1]. Western blot analysis confirmed
similar levels of expression of both the mutant G221S and the wt
StAR protein (Figure 6A). By contrast, the StAR mutation
T44H_S46X which is predicted to shorten the StAR protein
from 285 amino acids to only 45 amino acids, was not detected in
our Western blots, either due to degradation of smaller protein
fragment or smaller fragment running off the gel. Assessment of
pregnenolone production in cell supernatants by ELISA revealed
similar pregnenolone production rate for the T44H_S46X mutant
as for vector control (data not shown on the graph). By contrast,
compared to the wt StAR the G221S mutant produced 30–50%
pregnenolone over the observation period of 5–600 min while the
L260P mutant (which is associated with severe CLAH [32])
produced pregnenolone only to the basal levels of the vector
control (Figure 6B).
Discussion
Two siblings (a boy and a girl) were diagnosed 30 years ago with
congenital adrenal hyperplasia and were treated with glucocorti-
coids and mineralocorticoids although no clear signs of salt loss
were present except for a moderately elevated PRA in the girl.
Mineralocorticoid therapy was withdrawn in the boy at the age of
17 years without clinical problems as expected, while the sister
continues with the therapy due to moderately low plasma sodium
values with normal potassium levels, although the PRA has not
been assessed further. These familial cases were considered to have
a FGD syndrome and analyzed for the candidate genes. After
finding that MC2R and MRAP gene sequences were normal, two
novel StAR mutations were identified, one of paternal, the other of
maternal origin. This raises the number of families with reported
late-onset, nonclassic CLAH (NCLAH) with StAR mutations to
over 10 (Table 1).
Like in other reported cases of NCLAH (Table 1), gonadal
function was normal during fetal life in the boy and in both siblings
during pubertal development and through adulthood up to their
present age. The female patient has regular menses and normal
gonadotropin levels at the age of 32 years; the male patient has
normal serum testosterone with gonadotropin levels at the upper
normal limit and inhibin B in the lower normal range at age 29
years. As neither of them has attempted to have children, fertility
remains unanswered. Similarly, evolution of their gonadal function
remains uncertain. The cases of (N)CLAH reported to date show a
wide variation in the gonadal function involvement in both
females and males. In 46,XX females, this may range from normal
fertility and age at menopause to infertility, progressive increase in
LH and development of ovarian cysts [2,33,34]. In 46,XY
individuals sexual development may be severely affected or only
minor anomalies may be found (hypospadias and/or cryptorchi-
dism) or even absent at birth [1,2,3,4,5,32,35]. Accordingly,
46,XY individuals without major genital anomalies may have
normal pubertal development and adulthood sexual function;
however, infertility may also develop gradually with age [4]. The
overall sex difference in gonadal failure, which is even seen with
the loss-of-function StAR mutations, is thought to be explained by
the fact that the ovaries are quiescent and inactive from fetal life to
puberty but the testes are fully active in a 46,XY fetus [2,33].
Therefore, as the stimulation of steroidogenesis in a StAR deficient
milieu will lead to accumulation of cholesterol and cell damage
Table 1. Missense mutations identified in patients manifesting with non-classic StAR deficiency.
Mutation
H=homozygote;
C=compound
heterozygote*
Number
of families
Karyotype
in reported
patients
Age at manifestation of clinical signs
(A=adrenal, S=sexual development/
reproduction)
In vitro
activity (% of
wild-type)*** Ref.
AS
V187M H 1 XX 4.5 yrs – 22 3
R188C H and C 7 XX and XY 1–58 yrs Variable at birth with none in XX or
cryptorchidism and mild hypospadias
in few XY; some fertility issues
in XY adults
8–14 3, 4, 5
R192C H 1 XX and XY 5 yrs Hypofertility at 25 yrs (XY) 40 4, 5
A218V C (p.Q258X) 2 XX and XY 2 wks Severe 46,XY DSD 14 36
G221D H 1 XX 11 mo – 3 5
G221S C (p.T44H_S46X) 1 XX and XY 10 mo – 30–50 This study
M225T C (p.Q258X) 1 XY 10 mo Severe 46,XY DSD 43 36
F267S C (p.L260P) 1 XY 10 wks Severe 46,XY DSD 6 5
L275P C (p.A218V) 1 XY 2 mo Severe 46,XY DSD 24 2
L260P** H 4 XX and XY At birth 46,XY DSD 3–10 5, 32
*Mutation on partner allele is given in brackets (p.).
**Loss of function mutation manifesting clinically at birth with signs of classic StAR deficiency. Data given for comparison.
***In vitro activity (% of WT) is assessed by pregnenolone production (immunoassay) in COS cells transfected with expression vectors for wild-type or mutant StARa n d
F2 (the fusion protein P450 side-chain cleavage/adrenodoxin/adrenodoxin reductase). Note that data derive from different laboratories employing similar assay systems.
doi:10.1371/journal.pone.0020178.t001
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damage steroidogenic cells to a lesser degree, and that the adrenal
cortex and the testes (both of which are fully active in utero) will be
affected earlier than the ovaries.
The age at the presentation and the diagnosis of adrenal failure
and the degree of mineralocorticoid deficiency show large
variations among the patients described (Table 1), ranging from
adrenal failure at 2–4 years of age with mild hyperreninemia in the
first described patients [3] to the lack of diagnosis and treatment at
58 years of age without evidence of mineralocorticoid deficiency in
another series [4]. Our patients presented with typical symptoms
of adrenal failure (hypoglycemia and dehydration) at the age of 10
and 14 months; both had cortisol deficiency but no obvious
mineralocorticoid deficiency.
To date 9 StAR mutations have been reported as causing
NCLAH because of clinical manifestations and/or in vitro
functional testing (Table 1). Recently, a comparison of three in
vitro assays to test StAR function revealed a significant inter- and
between assay variability with the best phenotype correlation
coming from the direct assays measuring pregnenolone production
[5]. It appeared that StAR mutations with more than 10–20% of
wt activity in vitro may rather manifest as NCLAH (or FGD) while
an activity of less than 10% may be found with severe forms of
CLAH. Concordant clinical and functional findings suggested that
NCLAH exists for StAR mutations V187M, R188C, R192C, and
G221S [3,4,5]. Similarly, G221D StAR was manifesting with
isolated cortisol deficiency, but revealed only 3% activity in the
functional assays [5]. As revealed by our structural model of StAR,
all these residues are at the cholesterol binding pocket with R188
making a direct contact with the cholesterol. A disruption in this
interaction by mutation of the R188 residue or the structural shifts
in the cholesterol binding pocket due to mutations of neighbouring
residues will likely cause disruption in either the binding or the
release of cholesterol. Although StAR mutations A218V, M225T
and L275P have been tested in vitro as being partially active (14%,
43%, 24% respectively), clinical findings of patients harboring
these mutations qualify for the classic form with neonatal onset of
disease and/or severe 46,XY DSD at birth [2,36]. The C-terminus
helix in StAR provides the boundary for cholesterol binding
pocket and both L260 and F267 are involved in interaction with
cholesterol during binding/release. The F267S mutation had low
in vitro activity, manifested with a severe form of 46,XY DSD and
early adrenal insufficiency (10 weeks) [5]; and qualifies therefore
for the classic form of CLAH.
In summary, we report two novel StAR mutations found in
compound heterozygote form in two related patients (sister and
brother) presenting with isolated glucocorticoid deficiency. The
T44H_S46X mutation encoded a 45 aa protein which was
completely inactive. The G221S StAR mutation retained more
than 30% of wt activity explaining the mild phenotype.
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